Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

Grants

Funding Acknowledgements

We thank the patients who participated in these studies and their supportive families, as well as the investigators and clinical research staff from the study centres. These studies were sponsored by Pharmacyclics LLC, an AbbVie Company. James P. Dean, MD, PhD, an employee of Pharmacyclics LLC, an AbbVie Company, contributed to manuscript development and data interpretation. Medical writing support was provided by Danielle Ippolito, PhD, CMPP, and funded by Pharmacyclics LLC, an AbbVie Company. JCB was supported by R35 CA197734 (this funding is independent of the current studies in the pooled analysis).